169 related articles for article (PubMed ID: 35506698)
21. Antifungal prophylaxis in adult lung transplant recipients: Uncertainty despite 30 years of experience. A systematic review of the literature and network meta-analysis.
Marinelli T; Davoudi S; Foroutan F; Orchanian-Cheff A; Husain S
Transpl Infect Dis; 2022 Jun; 24(3):e13832. PubMed ID: 35388588
[TBL] [Abstract][Full Text] [Related]
22. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation.
Alexander BD; Dodds Ashley ES; Addison RM; Alspaugh JA; Chao NJ; Perfect JR
Transpl Infect Dis; 2006 Mar; 8(1):13-20. PubMed ID: 16623816
[TBL] [Abstract][Full Text] [Related]
23. Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey.
He SY; Makhzoumi ZH; Singer JP; Chin-Hong PV; Arron ST
Transpl Infect Dis; 2015 Feb; 17(1):14-20. PubMed ID: 25620387
[TBL] [Abstract][Full Text] [Related]
24. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.
Perfect JR; Dodds Ashley E; Drew R
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S207-10. PubMed ID: 15546119
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic antifungal agents used after lung transplantation.
Marino E; Gallagher JC
Ann Pharmacother; 2010 Mar; 44(3):546-56. PubMed ID: 20179260
[TBL] [Abstract][Full Text] [Related]
26. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients.
Palmer SM; Drew RH; Whitehouse JD; Tapson VF; Davis RD; McConnell RR; Kanj SS; Perfect JR
Transplantation; 2001 Aug; 72(3):545-8. PubMed ID: 11502995
[TBL] [Abstract][Full Text] [Related]
27. A novel approach to reducing hepatotoxicity related to fungal prophylaxis in pediatric lung transplant recipients.
Patz-Sobczak C; Young J; Bunton D; Kuklinski C; Estabrook M
Pediatr Transplant; 2024 May; 28(3):e14740. PubMed ID: 38616325
[TBL] [Abstract][Full Text] [Related]
28. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients.
Tollemar J; Andersson S; Ringdén O; Tydén G
Mycoses; 1992; 35(9-10):215-20. PubMed ID: 1291871
[TBL] [Abstract][Full Text] [Related]
29. Necrotizing Microascus tracheobronchitis in a bilateral lung transplant recipient.
Taton O; Bernier B; Etienne I; Bondue B; Lecomte S; Knoop C; Jacob F; Montesinos I
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29120502
[TBL] [Abstract][Full Text] [Related]
30. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy.
Singh N; Paterson DL; Gayowski T; Wagener MM; Marino IR
Transplantation; 2001 Apr; 71(7):910-3. PubMed ID: 11349726
[TBL] [Abstract][Full Text] [Related]
31. Aerosolized amphotericin B lipid complex as adjunctive treatment for fungal lung infection in patients with cancer-related immunosuppression and recipients of hematopoietic stem cell transplantation.
Safdar A; Rodriguez GH
Pharmacotherapy; 2013 Oct; 33(10):1035-43. PubMed ID: 23784915
[TBL] [Abstract][Full Text] [Related]
32. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.
Sun HY; Cacciarelli TV; Singh N
Transplantation; 2013 Sep; 96(6):573-8. PubMed ID: 23842191
[TBL] [Abstract][Full Text] [Related]
33. Safety of anidulafungin in solid organ transplant recipients.
Aguado JM; Varo E; Usetti P; Pozo JC; Moreno A; Catalán M; Len O; Blanes M; Solé A; Muñoz P; Montejo M;
Liver Transpl; 2012 Jun; 18(6):680-5. PubMed ID: 22328277
[TBL] [Abstract][Full Text] [Related]
34. Amphotericin B formulations: a comparative review of efficacy and toxicity.
Hamill RJ
Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
[TBL] [Abstract][Full Text] [Related]
35. Prospective interventional study to evaluate the efficacy and safety of liposomal amphotericin B as prophylaxis of fungal infections in high-risk liver transplant recipients.
Castroagudín JF; Pontón C; Bustamante M; Otero E; Martínez J; Tomé S; Conde R; Segade FR; Delgado M; Brage A; Galbán C; Varo E
Transplant Proc; 2005 Nov; 37(9):3965-7. PubMed ID: 16386598
[TBL] [Abstract][Full Text] [Related]
36. Echinocandin use in lung transplant recipients.
Al Jishi Y; Rotstein C; Kumar D; Humar A; Singer LG; Keshavjee S; Husain S
Clin Transplant; 2018 Dec; 32(12):e13437. PubMed ID: 30375050
[TBL] [Abstract][Full Text] [Related]
37. Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital.
Ringdén O
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():51-5. PubMed ID: 11801582
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology of invasive fungal infections in lung transplant recipients on long-term azole antifungal prophylaxis.
Chong PP; Kennedy CC; Hathcock MA; Kremers WK; Razonable RR
Clin Transplant; 2015 Apr; 29(4):311-8. PubMed ID: 25604399
[TBL] [Abstract][Full Text] [Related]
39. Variation in antifungal prophylaxis strategies in lung transplantation.
Husain S; Zaldonis D; Kusne S; Kwak EJ; Paterson DL; McCurry KR
Transpl Infect Dis; 2006 Dec; 8(4):213-8. PubMed ID: 17116134
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis with nebulized liposomal amphotericin B for Aspergillus infection in lung transplant patients does not cause changes in the lipid content of pulmonary surfactant.
Monforte V; López-Sánchez A; Zurbano F; Ussetti P; Solé A; Casals C; Cifrian J; de Pablos A; Bravo C; Román A
J Heart Lung Transplant; 2013 Mar; 32(3):313-9. PubMed ID: 23332731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
